More than 5,000 potential treatments for rare diseases are currently languishing on pharmaceutical company shelves, representing a vast, untapped reservoir of medical innovation. These are not merely nascent ideas but often drug candidates that have undergone substantial preclinical, toxicology, or even early-stage clinical work before being deprioritized or abandoned. The Children’s Tumor Foundation (CTF), a leading nonprofit organization, is spearheading an ambitious initiative to bridge this critical gap, transforming these dormant assets into life-changing therapies for patients with neurofibromatosis (NF) and other rare conditions.
The scale of this challenge is immense. According to Annette Bakker, PhD, CEO of the Children’s Tumor Foundation, the sheer volume of shelved assets underscores a systemic inefficiency in the drug development pipeline. For patients grappling with rare diseases, which collectively affect an estimated 30 million Americans, this backlog represents a profound missed opportunity. Each shelved compound carries with it the potential for a breakthrough, a lifeline that remains out of reach due to commercial dynamics rather than scientific merit. CTF, which has already proven its mettle as a "drug discovery engine" for neurofibromatosis, is now strategically pivoting to unlock this hidden potential.
The Commercial Imperative: Why Promising Drugs Are Shelved
The reasons behind the shelving of drug assets are complex, primarily driven by commercial considerations that often overshadow scientific promise or patient need. Major pharmaceutical companies operate under immense pressure to deliver high returns on investment, leading them to prioritize drugs with blockbuster potential – those targeting large patient populations and promising substantial market share. Rare diseases, by their very definition, affect small numbers of people, making the economic viability of developing treatments less attractive under traditional models.
One common scenario involves mergers and acquisitions. Larger pharmaceutical entities frequently acquire smaller biotechs, not for their entire portfolio, but for one or two specific, highly promising candidates. The remaining assets, despite having undergone significant initial development, may not align with the acquiring company’s strategic focus or therapeutic areas. These drugs, having absorbed hundreds of millions of dollars in research and development, are then written off as a loss and effectively shelved.
Another contributing factor is the breakdown of partnerships between biotechs and larger pharma companies. A promising collaboration might falter due to shifting priorities, financial constraints, or differing strategic visions. When such partnerships collapse, smaller biotechs often lack the substantial financial resources and infrastructure required to continue development independently. Their valuable data and compounds then become inaccessible, gathering dust in corporate archives. Furthermore, when a biotech company faces insolvency or goes under, the intellectual property and preclinical data associated with its assets can become entangled in legal and administrative complexities, rendering them practically irretrievable for further development.
Dr. Bakker emphasizes the profound inefficiency of this system. "Shelved assets are our focus because a shelved asset has already undergone a lot of development, a company has maybe already spent hundreds of millions of dollars on them, and they are now written off as a loss," she states. "What if we could take those and put them right into clinical trials? We could win all those years of preclinical and toxicology and go into clinical almost immediately." This perspective highlights the tremendous time and cost savings inherent in repurposing these compounds, potentially accelerating the availability of new treatments by years.
CTF’s Proven Track Record: From Bench to Bedside in Neurofibromatosis
The Children’s Tumor Foundation is not new to pioneering drug development for rare diseases. The organization has established itself as a formidable force in driving research for neurofibromatosis (NF), a group of complex genetic disorders characterized by tumor growth on nerves throughout the body. NF affects approximately 1 in 2,000 to 3,000 people globally, encompassing various forms such as NF1, NF2, and Schwannomatosis, each presenting unique challenges.
CTF’s early strategic investments in foundational research laid the groundwork for significant breakthroughs. Specifically, the foundation funded crucial early-stage research into the use of MEK inhibitors as a therapeutic approach for NF. This prescient investment proved instrumental, as MEK inhibition targets a critical signaling pathway involved in the uncontrolled cell growth characteristic of NF tumors. The success of this early funding culminated in the development and FDA approval of the only two treatments specifically indicated for NF: selumetinib (Koselugo) for inoperable plexiform neurofibromas in pediatric NF1 patients, and trametinib (Mekinist) in some contexts. These approvals were monumental, offering the first real hope for patients who previously had limited to no therapeutic options beyond surgery or radiation. The journey from initial CTF-funded research to FDA-approved therapies underscores the foundation’s capacity to identify and nurture promising scientific avenues.
Building on this success, CTF is now leveraging its deep understanding of drug discovery, its extensive scientific network, and its patient advocacy infrastructure to tackle the challenge of shelved assets. The strategic shift is a natural evolution, recognizing that the quickest path to new treatments might not always be through de novo discovery, but through the intelligent resurrection of existing, underutilized compounds.
A Blueprint for Revival: The Gomekli Success Story
One of the most compelling examples of CTF’s vision brought to fruition is the successful rescue of Gomekli, a drug initially developed by Pfizer. Dr. Bakker played a pivotal role in convincing Pfizer to license this shelved asset to SpringWorks Therapeutics, a spin-off company established in 2017 with a unique business model focused on developing clinical-stage therapies for rare diseases.
The Gomekli story is a testament to the power of advocacy and strategic collaboration. Within Pfizer, dedicated "champions" like Freda Lewis-Hall, MD, and Lara Sullivan, MD, were instrumental in navigating internal complexities and advocating for the drug’s potential after engaging with Dr. Bakker and understanding the profound unmet need in the rare disease community. This internal advocacy, coupled with CTF’s persistent efforts, paved the way for Gomekli’s revival.
SpringWorks Therapeutics, founded specifically to advance these deprioritized programs, took Gomekli through the necessary clinical trials. The drug, which targets specific inoperable plexiform neurofibromas, received FDA approval last year, marking a monumental achievement for patients. The commercial success was equally striking: SpringWorks Therapeutics was subsequently acquired by Merck KGaA for an impressive $3.4 billion, validating the economic viability of this innovative model.
However, Dr. Bakker acknowledges that scaling this success presents challenges. "We are looking for these champions in other companies that are willing to work with us, but the pharma companies we are calling are not opening the door," she reveals. This highlights the inherent friction between the traditional commercial imperatives of large pharmaceutical companies and the humanitarian urgency of rare disease drug development. The Gomekli case, while a beacon of hope, also underscores the need for a more systemic shift in how the industry views and manages its dormant assets.
Overcoming the Intrinsic Hurdles of Rare Disease Drug Development
Developing drugs for rare diseases is inherently fraught with difficulties, often described as "ten times harder" than for common conditions. Dr. Bakker points to patient recruitment for clinical trials as one of the most significant obstacles. A rare disease, by definition, affects a small population – in the U.S., fewer than 200,000 people. This low prevalence means that patients are geographically dispersed, often across multiple countries, making it incredibly challenging and costly to identify, enroll, and retain enough participants for statistically meaningful clinical trials. Furthermore, many rare diseases are heterogeneous, with varying presentations and severities, which can complicate trial design and patient stratification.
This is where rare disease nonprofits, like the Children’s Tumor Foundation, provide an unparalleled advantage. These organizations are intrinsically connected to patient communities. They maintain registries, foster support networks, and build trust with patients and their families over years. This direct access to a well-informed and engaged patient cohort dramatically streamlines the recruitment process for clinical trials. Instead of starting from scratch, CTF can leverage its established network, significantly reducing the time and expense typically associated with patient enrollment. This inherent capability transforms a major hurdle into a competitive advantage for nonprofit-led initiatives.
Beyond patient recruitment, CTF has proactively built a robust preclinical infrastructure. This "preclinical hub" comprises a constantly growing network of sophisticated preclinical models, including advanced cellular assays and relevant animal models specific to neurofibromatosis. Once a pharmaceutical company agrees to license an asset to the foundation, CTF can efficiently put the drug through rigorous preclinical testing within this dedicated hub. This integrated approach ensures that the transition from a shelved asset to active development is as seamless and rapid as possible. "The idea is to create an ecosystem that makes sure that once we have the drug, we can be really efficient," Dr. Bakker explains, articulating a vision for a streamlined, end-to-end drug development pathway.
Broader Implications and The Future Landscape of Rare Disease Treatment
The Children’s Tumor Foundation’s innovative approach to rescuing shelved assets holds profound implications for the future of rare disease drug development. It challenges the traditional pharmaceutical model, suggesting a paradigm shift where philanthropic organizations and patient advocacy groups play a more central, proactive role in driving therapeutic innovation.
Firstly, this model offers a powerful ethical imperative. With thousands of potential treatments sitting idle, often with substantial safety and efficacy data, there is a moral obligation to explore every avenue to bring these compounds to patients in desperate need. CTF’s strategy transforms a corporate write-off into a potential medical breakthrough, turning lost investments into invaluable assets.
Secondly, it presents a compelling economic argument. By leveraging existing preclinical and early clinical data, CTF’s model drastically reduces the initial investment and development timeline typically associated with drug discovery. This efficiency can make previously "unprofitable" rare disease drugs economically viable, not just for nonprofits, but potentially for smaller biotechs or even larger pharma companies willing to adopt more flexible partnership models. The $3.4 billion acquisition of SpringWorks Therapeutics by Merck KGaA for a drug born from this model serves as a powerful validation of its financial potential.
The success of CTF also underscores the critical importance of collaboration. For this model to scale, there needs to be greater willingness from pharmaceutical companies to engage with nonprofit partners, to share data, and to license deprioritized assets. This collaboration could be fostered through various mechanisms, including open-innovation platforms, government incentives for asset sharing, or the establishment of more spin-off entities akin to SpringWorks. Regulatory bodies could also play a role by streamlining processes for drugs with existing human data, further accelerating their path to market.
Ultimately, the Children’s Tumor Foundation is not just seeking to rescue individual drugs; it is striving to transform the entire ecosystem of rare disease drug development. By creating a collaborative network that combines scientific expertise, patient advocacy, efficient preclinical infrastructure, and a strategic focus on underutilized assets, CTF offers a beacon of hope for the millions affected by rare diseases. It’s a vision where no promising therapy is left behind, and every patient has the chance for a life-changing treatment. The challenge is significant, but with continued advocacy and successful case studies like Gomekli, CTF is paving the way for a more equitable and efficient future in medical innovation.
